APA 7: TWs Editor. (2023, November 23). Long COVID Risk Reduced by COVID-19 Vaccination Prior to Infection, Study Finds. PerEXP Teamworks. [News Link]
Analyzing data from over half a million Swedish adults, the results indicate that individuals who remained unvaccinated were nearly four times more likely to receive a diagnosis of long COVID compared to those who received vaccination before their initial infection. While the researchers emphasize that direct causation cannot be conclusively inferred from this observational evidence, they underscore the significance of primary vaccination against COVID-19 as a crucial factor in mitigating the burden of post-COVID-19 conditions within the population.
While the effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe complications of acute COVID-19 is well-established, their efficacy in preventing long COVID has been less definitively understood due to the reliance on self-reported symptoms in most prior studies.
To delve into this issue, researchers delved into the effectiveness of initial COVID-19 vaccination, encompassing the first two doses and the initial booster dose within the recommended schedule, against post-COVID-19 conditions. This investigation utilized data from the SCIFI-PEARL project, a register-based study focused on the COVID-19 pandemic’s impact in Sweden.
The study encompassed 589,722 adults aged 18 and over in the two largest regions of Sweden, all with a recorded first COVID-19 infection occurring between December 27, 2020, and February 9, 2022.
Participants were monitored from their initial COVID-19 infection until the occurrence of a post-COVID-19 condition diagnosis, vaccination, reinfection, death, emigration, or the conclusion of the follow-up period on November 30, 2022—whichever transpired first. The average follow-up duration was 129 days for the entire study population, with vaccinated individuals having an average follow-up of 197 days and those not vaccinated having an average follow-up of 112 days.
Those individuals who had received at least one dose of a COVID-19 vaccine before their infection were classified as vaccinated. In the analysis, a comprehensive array of factors—including age, sex, pre-existing health conditions, the number of healthcare contacts in 2019, educational attainment, employment status, and the predominant virus variant at the time of infection—were taken into consideration.
Among the 299,692 individuals who were vaccinated and subsequently contracted COVID-19, only 1,201 individuals (0.4%) were diagnosed with post-COVID-19 conditions during the follow-up period. In contrast, among the 290,030 individuals who remained unvaccinated, 4,118 individuals (1.4%) received a diagnosis of post-COVID-19 conditions.
Individuals who had received one or more COVID-19 vaccines before their initial infection showed a 58% lower likelihood of being diagnosed with post-COVID-19 conditions compared to those who remained unvaccinated.
Moreover, a clear dose-response effect was observed, indicating an increase in vaccine effectiveness with each successive dose before infection. Specifically, the first dose resulted in a 21% reduction in the risk of post-COVID-19 conditions, two doses reduced the risk by 59%, and three or more doses were associated with a 73% decrease in the risk of post-COVID-19 conditions.
It’s essential to note that this study is observational, offering evidence that is less definitive in establishing causality. The researchers acknowledge various limitations, including the restricted data available on symptoms associated with post-COVID-19 conditions, the yet-to-be-validated diagnosis code, potential influences of reinfections on vaccine effectiveness, and pre-existing expectations regarding the protective impact of vaccination.
Despite these considerations, the study stands out for its substantial scale and meticulous design, relying on high-quality, individual-level registry data. This approach minimizes the risk of self-reporting bias and lends strength to the robustness of the findings.
The authors emphasize the significance of comprehensive primary vaccination coverage against COVID-19, not only for diminishing the risk of severe acute infection but also for alleviating the burden of post-COVID-19 conditions within the population. When considering these results in conjunction with evidence from other studies, a clear association emerges between the immune system and the emergence of post-viral conditions. The researchers stress the critical role of timely vaccination in the context of pandemics, underscoring its importance in mitigating both acute infections and potential long-term consequences.
The authors advocate for sustained exploration into the ongoing development of persistent symptoms in the aftermath of COVID-19 and other viral infections. Additionally, they emphasize the need for initiatives aimed at enhancing the precision of documenting both recovery and lingering illness post-infection. Furthermore, the authors highlight the importance of quantifying critical outcomes related to family, social, financial, and economic aspects. These measures, they contend, are essential for gaining a comprehensive understanding of the broader impact of infections and improving strategies for long-term health management.
The researchers underscore that these estimates play a crucial role in securing the necessary funding for future research initiatives and fostering greater investment in specialized clinical services. These services aim to provide essential treatment and rehabilitation support for individuals grappling with post-viral conditions. In essence, the figures derived from studies like this are pivotal for advocating financial support and resource allocation to address the challenges posed by long-term health consequences of viral infections.
Resources
- ONLINE NEWS British Medical Journal. (2023, November 22). COVID-19 vaccination before infection strongly linked to reduced risk of developing long COVID. Medical Xpress. [Medical Xpress]
- JOURNAL Lundberg-Morris, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023). Covid-19 Vaccine Effectiveness Against Post-Covid-19 Condition Among 589,722 Individuals in Sweden: Population Based Cohort Study. BMJ, 383, e076990. [BMJ]
